
argenx (ARGX) Stock Forecast & Price Target
argenx (ARGX) Analyst Ratings
Bulls say
argenx is poised for long-term success due to its strong pipeline of potential treatments for rare autoimmune diseases, as seen through the successful FDA approvals and ongoing clinical trials. While facing competition in the market, argenx's solid financial position and continued progress in its various programs suggest potential for future growth and success. However, it is worth noting that as with any drug development company, there is risk involved in clinical trials and potential dilution risk for shareholders in the future.
Bears say
argenx is a biopharmaceutical company that has received FDA approval for its lead product, Vyvgart and Vyvgart Hytrulo, for the treatment of rare autoimmune diseases. Despite a strong pipeline, there are risks to the company's stock and rating, such as potential clinical, regulatory, or commercial failures for its products, efgartigimod and ARGX-117. These risks may hinder the attainment of its price target and rating.
This aggregate rating is based on analysts' research of argenx and is not a guaranteed prediction by Public.com or investment advice.
argenx (ARGX) Analyst Forecast & Price Prediction
Start investing in argenx (ARGX)
Order type
Buy in
Order amount
Est. shares
0 shares